ProteoThera, Inc.

Biotechnology ResearchMassachusetts, United States2-10 Employees

ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology.  The Company's transformative platform technology, a proprietary tissue matrix-binding (MB) protein fusion technology, is being developed to improve clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration. 

The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally or subcutaneous delivered proteins, peptides, and small molecules. ProteoThera’s focus on previously validated or approved therapies greatly de-risks the clinical, regulatory, and commercail pathways. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

ProteoThera’s first development priority is the use of PRT-1000 (MB - Interleukin 1 Receptor Antagonist (MB-IL1RA) for treatment of acute gout pain. IL1RA is a potent cytokine inhibitor, already FDA approved for systemic administration in rheumatoid arthritis. Gout is a large and growing market with total gout drug sales projected to double to more than $2 Billion by 2018 in the US and Europe.

The MB targeting technology was developed at Brigham and Women’s Hospital and Harvard Medical School.

Sign up for free to view info

Email Format Employee directory